VANDA PHARMACEUTICALS INC. (NASDAQ:VNDA) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

Vanda Pharmaceuticals Inc. Exhibit
EX-99.1 2 d426904dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results     •   Total net product sales were $42.1 million in the second quarter of 2017     •   Hetlioz® net product sales grew to $22.5 million in the second quarter of 2017     •   Fanapt® net product sales grew to $19.5 million in the second quarter of 2017     •   Vanda reiterates 2017 net product sales guidance of $165 million to $175 million WASHINGTON – August 2,…
To view the full exhibit click here

About VANDA PHARMACEUTICALS INC. (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. The Company offers HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). The Company offers Fanapt (iloperidone) for the treatment of schizophrenia. Additionally, its distribution partners launched Fanapt in Israel and Mexico. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. It is indicated for the treatment of CNS Disorders.